Country: Switzerland

Currently showing 1 clinical trials. Use pagination links to see more trials.

Select your city to get better results

Select your region to filter trials in your city or near you.

  • CT-EU-00117325

    Intravenous treatment with ANV419 — a new therapy for patients with advanced melanoma

    The aim of this clinical trial is to test a new combination treatment for advanced melanoma. The treatment involves taking special immune cells called tumor-infiltrating lymphocytes (TILs for short) from a patient’s tumor and growing them in the laboratory. These TILs are then returned to the patient via intravenous infusion along with a new drug called ANV419.

    ANV419 is designed to help TILs grow and multiply even more once they are back in the patient’s body. Researchers predict that these special TIL cells will be able to better recognize and attack cancer cells, helping the patient’s immune system fight melanoma.

    Doctors will closely monitor any side effects patients experience with the new therapy. They will check whether any adverse events occur, and if they do occur, how often they occur and how serious they may be. The entire study will last about a year, with regular follow-up visits to monitor the effectiveness of the treatment and the patient’s well-being.

    • Tumor-infiltrating lymphocytes (TILs)
    • ANV419